The emerging role of lysophosphatidic acid in cancer (original) (raw)

• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  CAS PubMed Google Scholar
• van Corven, E. J., Groenink, A., Jalink, K., Eichholtz, T. & Moolenaar, W. H. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell 59, 45–54 (1989). Seminal observation that LPA has growth-factor-like activities, and signals in a strictly G-protein-dependent manner.
  CAS PubMed Google Scholar
• Imamura, F. et al. Induction of in vitro tumour cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D. Biochem. Biophys. Res. Commun. 193, 497–503 (1993).
  CAS PubMed Google Scholar
• Jalink, K., Hordijk, P. L. & Moolenaar, W. H. Growth factor-like effects of lysophosphatidic acid, a novel lipid mediator. Biochim. Biophys. Acta 1198, 185–196 (1994).
  PubMed Google Scholar
• Xu, Y., Fang, X. J., Casey, G. & Mills, G. B. Lysophospholipids activate ovarian and breast cancer cells. Biochem. J. 309, 933–940 (1995).
  CAS PubMed PubMed Central Google Scholar
• Xu, Y., Casey, G. & Mills, G. B. Effect of lysophospholipids on signaling in the human Jurkat T cell line. J. Cell Physiol. 163, 441–450 (1995).
  CAS PubMed Google Scholar
• Levine, J. S., Koh, J. S., Triaca, V. & Lieberthal, W. Lysophosphatidic acid: a novel growth and survival factor for renal proximal tubular cells. Am. J. Physiol. 273, F575–F585 (1997).
  CAS PubMed Google Scholar
• Altun-Gultekin, Z. F. et al. Activation of Rho-dependent cell spreading and focal adhesion biogenesis by the v-Crk adaptor protein. Mol. Cell Biol. 18, 3044–3058 (1998).
  CAS PubMed PubMed Central Google Scholar
• Stam, J. C., Michiels, F., van der Kammen, R. A., Moolenaar, W. H. & Collard, J. G. Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. EMBO J. 17, 4066–4074 (1998).
  CAS PubMed PubMed Central Google Scholar
• Weiner, J. A. & Chun, J. Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid. Proc. Natl Acad. Sci. USA 96, 5233–5238 (1999).
  CAS PubMed PubMed Central Google Scholar
• Jalink, K., Eichholtz, T., Postma, F. R., van Corven, E. J. & Moolenaar, W. H. Lysophosphatidic acid induces neuronal shape changes via a novel, receptor-mediated signaling pathway: similarity to thrombin action. Cell Growth Differ. 4, 247–255 (1993). First demonstration that LPA induces neurite retraction in neuroblastoma cells.
  CAS PubMed Google Scholar
• Jalink, K., van Corven, E. J., Hengeveld, T., Morii, N., Narumiya, S. & Moolenaar, W. H. Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho. J. Cell Biol. 126, 801–810 (1994). First paper indicating a role for RHOA in LPA-induced 'dedifferentiation' of neuroblastoma cells, independently of classic second messengers.
  CAS PubMed Google Scholar
• Hill, C. S., Oh, S. Y., Schmidt, S. A., Clark, K. J. & Murray, A. W. Lysophosphatidic acid inhibits gap-junctional communication and stimulates phosphorylation of connexin-43 in WB cells: possible involvement of the mitogen-activated protein kinase cascade. Biochem. J. 303, 475–479 (1994).
  PubMed PubMed Central Google Scholar
• Tigyi, G. et al. Lysophosphatidic acid-induced neurite retraction in PC12 cells: control by phosphoinositide-Ca2+ signaling and Rho. J. Neurochem. 66, 537–548 (1996).
  CAS PubMed Google Scholar
• Schulze, C., Smales, C., Rubin, L. L. & Staddon, J. M. Lysophosphatidic acid increases tight junction permeability in cultured brain endothelial cells. J. Neurochem. 68, 991–1000 (1997).
  CAS PubMed Google Scholar
• Postma, F. R. et al. Acute loss of cell–cell communication caused by G protein-coupled receptors: a critical role for c-Src. J. Cell Biol. 140, 1199–1209 (1998).
  CAS PubMed PubMed Central Google Scholar
• van Nieuw Amerongen, G. P., Vermeer, M. A. & van Hinsbergh, V. W. Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler. Thromb. Vasc. Biol. 20, E127–E133 (2000).
  CAS PubMed Google Scholar
• Pustilnik, T. B. et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin. Cancer Res. 5, 3704–3710 (1999).
  CAS PubMed Google Scholar
• Palmetshofer, A., Robson, S. C. & Nehls, V. Lysophosphatidic acid activates nuclear factor kappa B and induces proinflammatory gene expression in endothelial cells. Thromb. Haemost. 82, 1532–1537 (1999).
  CAS PubMed Google Scholar
• Schwartz, B. M. et al. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol. Oncol. 81, 291–300 (2001).
  CAS PubMed Google Scholar
• Fishman, D. A., Liu, Y., Ellerbroek, S. M. & Stack, M. S. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 61, 3194–3199 (2001).
  CAS PubMed Google Scholar
• Zheng, Y., Kong, Y. & Goetzl, E. J. Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J. Immunol. 166, 2317–2322 (2001).
  CAS PubMed Google Scholar
• Hu, Y. L. et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J. Natl Cancer Inst. 93, 762–768 (2001).
  CAS PubMed Google Scholar
• Gschwind, A., Hart, S., Fischer, O. M. & Ullrich, A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. EMBO J. 22, 2411–2421 (2003). Novel mechanism for transactivation of tyrosine-kinase receptors by G-protein-coupled receptors.
  CAS PubMed PubMed Central Google Scholar
• Fang, X. et al. Mechanisms of lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J. Biol. Chem. (in the press).
• Sturm, A., Sudermann, T., Schulte, K. M., Goebell, H. & Dignass, A. U. Modulation of intestinal epithelial wound healing in vitro and in vivo by lysophosphatidic acid. Gastroenterology 117, 368–377 (1999).
  CAS PubMed Google Scholar
• Lee, H., Goetzl, E. J. & An, S. Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing. Am. J. Physiol. Cell Physiol. 278, C612–C618 (2000).
  CAS PubMed Google Scholar
• Watsky, M. A., Griffith, M., Wang, D. A. & Tigyi, G. J. Phospholipid growth factors and corneal wound healing. Ann. NY Acad. Sci. 905, 142–158 (2000).
  CAS PubMed Google Scholar
• Balazs, L., Okolicany, J., Ferrebee, M., Tolley, B. & Tigyi, G. Topical application of the phospholipid growth factor lysophosphatidic acid promotes wound healing in vivo. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280, R466–R472 (2001).
  CAS PubMed Google Scholar
• Daub, H., Weiss, F. U., Wallasch, C. & Ullrich, A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 379, 557–560 (1996). Demonstration of cross-talk between G-protein-coupled receptors and receptor protein tyrosine kinases.
  CAS PubMed Google Scholar
• Prenzel, N. et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402, 884–888 (1999).
  CAS PubMed Google Scholar
• Hordijk, P. L., Verlaan, I., van Corven, E. J. & Moolenaar, W. H. Protein tyrosine phosphorylation induced by lysophosphatidic acid in Rat-1 fibroblasts. Evidence that phosphorylation of map kinase is mediated by the Gi-p21ras pathway. J. Biol. Chem. 269, 645–651 (1994).
  CAS PubMed Google Scholar
• Kumagai, N., Morii, N., Fujisawa, K., Nemoto, Y., & Narumiya, S. ADP-ribosylation of rho p21 inhibits lysophosphatidic acid-induced protein tyrosine phosphorylation and phosphatidylinositol 3-kinase activation. J. Biol. Chem. 268, 24535–24538 (1993).
  CAS PubMed Google Scholar
• Holtsberg, F. W. et al. Lysophosphatidic acid induces necrosis and apoptosis in hippocampal neurons. J. Neurochem. 70, 66–76 (1998).
  CAS PubMed Google Scholar
• Holtsberg, F. W. et al. Lysophosphatidic acid and apoptosis of nerve growth factor-differentiated PC12 cells. J. Neurosci. Res. 53, 685–696 (1998).
  CAS PubMed Google Scholar
• Okusa, M. D. et al. Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol. 27 May 2003 [epub ahead of print]. Use of receptor-selective LPA agonists and antagonists in vivo to define the function and role of particular LPA receptors in ischaemia reperfusion.
• Tokumura, A. et al. Lysophosphatidic acids induce proliferation of cultured vascular smooth muscle cells from rat aorta. Am. J. Physiol. 267, C204–C210 (1994).
  CAS PubMed Google Scholar
• Tokumura, A., Yotsumoto, T., Masuda, Y. & Tanaka, S. Vasopressor effect of lysophosphatidic acid on spontaneously hypertensive rats and Wistar Kyoto rats. Res. Commun. Mol. Pathol. Pharmacol. 90, 96–102 (1995).
  CAS PubMed Google Scholar
• Cerutis, D. R. et al. Lysophosphatidic acid and EGF stimulate mitogenesis in human airway smooth muscle cells. Am. J. Physiol. 273, L10–L15 (1997).
  CAS PubMed Google Scholar
• Toews, M. L., Ustinova, E. E. & Schultz, H. D. Lysophosphatidic acid enhances contractility of isolated airway smooth muscle. J. Appl. Physiol. 83, 1216–1222 (1997).
  CAS PubMed Google Scholar
• Rizza, C. et al. Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction. Lab. Invest. 79, 1227–1235 (1999).
  CAS PubMed Google Scholar
• Scalia, R., Pruefer, D. & Lefer, A. M. A novel lysophosphatidic acid analog, LXR-1035, inhibits leukocyte-endothelium interaction via inhibition of cell adhesion molecules. J. Leukoc. Biol. 67, 26–33 (2000).
  CAS PubMed Google Scholar
• Hayashi, K. et al. Phenotypic modulation of vascular smooth muscle cells induced by unsaturated lysophosphatidic acids. Circ. Res. 89, 251–258 (2001).
  CAS PubMed Google Scholar
• Natarajan, V., Scribner, W. M., Hart, C. M. & Parthasarathy, S. Oxidized low density lipoprotein-mediated activation of phospholipase D in smooth muscle cells: a possible role in cell proliferation and atherogenesis. J. Lipid Res. 36, 2005–2016 (1995).
  CAS PubMed Google Scholar
• Siess, W. et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl Acad. Sci. USA 96, 6931–6936 (1999). Clear implication of LPA in atherosclerosis.
  CAS PubMed PubMed Central Google Scholar
• Schmidt, A. et al. Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid. Nature 401, 133–141 (1999). Demonstration of a potential role for intracellular LPA in vesicle formation.
  CAS PubMed Google Scholar
• McIntyre, T. M. et al. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc. Natl Acad. Sci. USA 100, 131–136 (2003). Potential novel function for intracelullar LPA in the activation of the transcription factor PPARγ.
  CAS PubMed Google Scholar
• van Corven, E. J., Hordijk, P. L., Medema, R. H., Bos, J. L. & Moolenaar, W. H. Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts. Proc. Natl Acad. Sci. USA 90, 1257–1261 (1993). First paper showing that G-protein-coupled receptor ligands, including LPA, can activate RAS via pertussis-toxin-sensitive G i and a putative protein tyrosine kinase.
  CAS PubMed PubMed Central Google Scholar
• van Dijk, M. C. et al. Exogenous phospholipase D generates lysophosphatidic acid and activates Ras, Rho and Ca2+ signaling pathways. Curr. Biol. 8, 386–392 (1998). First demonstration that a secreted phospholipase D (of bacterial origin) can generate LPA and activate LPA signalling pathways in mammalian cells.
  CAS PubMed Google Scholar
• Kranenburg, O. et al. Activation of RhoA by lysophosphatidic acid and G12/13 subunits in neuronal cells: induction of neurite retraction. Mol. Biol. Cell 10, 1851–1857 (1999).
  CAS PubMed PubMed Central Google Scholar
• Fang, X. et al. Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem. J. 352, 135–143 (2000).
  CAS PubMed PubMed Central Google Scholar
• Fang, X. et al. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann. NY Acad. Sci. 905, 188–208 (2000).
  CAS PubMed Google Scholar
• Kranenburg, O. & Moolenaar, W. H. Ras-MAP kinase signalling by lysophosphatidic acid and other G protein-coupled receptor agonists. Oncogene 20, 1540–1546 (2001).
  CAS PubMed Google Scholar
• Van Leeuwen, F. N. et al. Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1. J. Biol. Chem. 278, 400–406 (2003). Shows that LPA1 receptors signal RAC activation and cell migration via the invasion-inducing GDP/GTP exchange factor TIAM1.
  CAS PubMed Google Scholar
• Etienne-Manneville, S. & Hall, A. Rho GTPases in cell biology. Nature 420, 629–635 (2002).
  CAS PubMed Google Scholar
• Takeda, H. et al. PI 3-kinase gamma and protein kinase C-zeta mediate RAS-independent activation of MAP kinase by a Gi protein-coupled receptor. EMBO J. 18, 386–395 (1999).
  CAS PubMed PubMed Central Google Scholar
• Malliri, A. et al. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature 417, 867–871 (2002).
  CAS PubMed Google Scholar
• Hecht, J. H., Weiner, J. A., Post, S. R. & Chun, J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell. Biol. 135, 1071–1083 (1996). Identification and cloning of the first LPA receptor.
  CAS PubMed Google Scholar
• An, S., Dickens, M. A., Bleu, T., Hallmark, O. G. & Goetzl, E. J. Molecular cloning of the human Edg2 protein and its identification as a functional cellular receptor for lysophosphatidic acid. Biochem. Biophys. Res. Commun. 231, 619–622 (1997).
  CAS PubMed Google Scholar
• An, S., Bleu, T., Hallmark, O. G. & Goetzl, E. J. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J. Biol. Chem. 273, 7906–7910 (1998). Identification and cloning of the second LPA receptor.
  CAS PubMed Google Scholar
• Bandoh, K. et al. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J. Biol. Chem. 274, 27776–27785 (1999). Cloning of EDG7/LPA3 , the third LPA receptor.
  CAS PubMed Google Scholar
• Im, D. S. et al. Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol. Pharmacol. 57, 753–759 (2000). Cloning of the third LPA receptor EDG7 /LPA3 from prostate cancer cells.
  CAS PubMed Google Scholar
• Hla, T., Lee, M. J., Ancellin, N., Paik, J. H. & Kluk, M. J. Lysophospholipids — receptor revelations. Science 294, 1875–1878 (2001).
  CAS PubMed Google Scholar
• Noguchi, K., Ishii, S. & Shimizu, T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J. Biol. Chem. 30 Apr 2003 [epub ahead of print]. Identification of the fourth LPA receptor, LPA4.
• Contos, J. J. & Chun, J. The mouse lp(A3)/Edg7 lysophosphatidic acid receptor gene: genomic structure, chromosomal localization, and expression pattern. Gene 267, 243–253 (2001).
  CAS PubMed Google Scholar
• Fang, X. et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim. Biophys. Acta 1582, 257–264 (2002).
  CAS PubMed Google Scholar
• Goetzl, E. J. et al. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer. Cancer Res. 59, 5370–5375 (1999).
  CAS PubMed Google Scholar
• Furui, T. et al. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin. Cancer Res. 5, 4308–4318 (1999).
  CAS PubMed Google Scholar
• Eder, A. M., Sasagawa, T., Mao, M., Aoki, J. & Mills, G. B. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin. Cancer Res. 6, 2482–2491 (2000).
  CAS PubMed Google Scholar
• Schulte, K. M., Beyer, A., Kohrer, K., Oberhauser, S. & Roher, H. D. Lysophosphatidic acid, a novel lipid growth factor for human thyroid cells: over-expression of the high-affinity receptor edg4 in differentiated thyroid cancer. Int. J. Cancer 92, 249–256 (2001).
  CAS PubMed Google Scholar
• Contos, J. J., Fukushima, N., Weiner, J. A. & Kaushal, D. J. Requirement for the LPA1 lysophosphatidic acid receptor gene in normal suckling behavior. Proc. Natl Acad. Sci. USA 97, 13384–13389 (2000). Shows that Lpa1 -knockout mice have reduced viability because of defects in suckling behaviour.
  CAS PubMed PubMed Central Google Scholar
• Contos, J. J. et al. Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2). Mol. Cell Biol. 22, 6921–6929 (2002). Shows that compound Lpa1/Lpa2 -knockout mice have a phenotype that is not significantly different from Lpa 1-knockout mice. This indicates redundancy in the system and strengthens the likelihood that drugs can be developed against LPA production or function.
  CAS PubMed PubMed Central Google Scholar
• Shida, D. et al. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1. Cancer Res. 63, 1706–1711 (2003).
  CAS PubMed Google Scholar
• Fischer, D. J. et al. Naturally occurring analogs of lysophosphatidic acid elicit different cellular responses through selective activation of multiple receptor subtypes. Mol. Pharmacol. 54, 979–988 (1998).
  CAS PubMed Google Scholar
• Erickson, J. R., Espinal, G. & Mills, G. B. Analysis of the EDG2 receptor based on the structure/activity relationship of LPA. Ann. N Y Acad. Sci. 905, 279–281 (2000).
  CAS PubMed Google Scholar
• Fischer, D. J. et al. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol. Pharmacol. 60, 776–784 (2001). Identification of a compound LPA1/LPA3 inhibitor. Low activity and stability limit use to in vitro studies.
  CAS PubMed Google Scholar
• Wang, D. A. et al. A single amino acid determines lysophospholipid specificity of the S1P1 (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors. J. Biol. Chem. 276, 49213–49220 (2001). Definition of the structural characteristics that determine whether S1P1 and LPA1 will bind their respective ligands.
  CAS PubMed Google Scholar
• Heise, C. E. et al. Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol. Pharmacol. 60, 1173–1180 (2001). Identification of a composite LPA1/LPA3 receptor antagonist with in vivo activity.
  CAS PubMed Google Scholar
• Hooks, S. B. et al. Lysophosphatidic acid-induced mitogenesis is regulated by lipid phosphate phosphatases and is Edg-receptor independent. J. Biol. Chem. 276, 4611–4621 (2001).
  CAS PubMed Google Scholar
• Hasegawa, Y. et al. Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J. Biol. Chem. 278, 11962–11969 (2003). Identification of a stable agonist of LPA3 with in vivo applicability.
  CAS PubMed Google Scholar
• Bandoh, K. et al. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure–activity relationship of cloned LPA receptors. FEBS Lett. 478, 159–165 (2000).
  CAS PubMed Google Scholar
• Virag, T. et al. Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol. Pharmacol. 63, 1032–1042 (2003). Rational drug design identifies novel receptor-selective agonists and antagonists.
  CAS PubMed Google Scholar
• Tigyi, G. & Miledi, R. Lysophosphatidates bound to serum albumin activate membrane currents in Xenopus oocytes and neurite retraction in PC12 pheochromacytoma cells. J. Biol. Chem. 267, 21360–21367 (1992).
  CAS PubMed Google Scholar
• Goetzl, E. J. et al. Gelsolin binding and cellular presentation of lysophosphatidic acid. J. Biol. Chem. 275, 14573–14578 (2000).
  CAS PubMed Google Scholar
• Eichholtz, T., Jalink, K., Fahrenfort, I. & Moolenaar, W. H. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J. 291, 677–680 (1993).
  CAS PubMed PubMed Central Google Scholar
• Aoki, J. et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J. Biol. Chem. 277, 48737–48744 (2002). Describes the biochemical pathways regulating LPA production in plasma and serum.
  CAS PubMed Google Scholar
• Sano, T. et al. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J. Biol. Chem. 277, 21197–21206 (2002). Elucidation of the mechanisms regulating the production of LPA in plasma and serum.
  CAS PubMed Google Scholar
• Imai, A., Furui, T., Tamaya, T. & Mills, G. B. A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells. J. Clin. Endocrinol. Metab. 85, 3370–3375 (2000).
  CAS PubMed Google Scholar
• Xu, J. et al. Lipid phosphate phosphatase-1 and Ca2+ control lysophosphatidate signaling through EDG-2 receptors. J. Biol. Chem. 275, 27520–27530 (2000). Strong evidence implicating LPPs in the degradation of LPA and in limiting LPA signalling.
  CAS PubMed Google Scholar
• Tokumura, A. et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J. Biol. Chem. 277, 39436–39442 (2002a).
  CAS PubMed Google Scholar
• Umezu-Goto, M. et al. Autotaxin has lysophospholipase D activity leading to tumour cell growth and motility by lysophosphatidic acid production. J. Cell Biol. 158, 227–233 (2002). Shows that the long sought after lysoPLD was actually autotaxin. Opened a whole new era in LPA function and potential therapeutic application.
  CAS PubMed PubMed Central Google Scholar
• Sciorra, V. A. & Morris, A. J. Roles for lipid phosphate phosphatases in regulation of cellular signaling. Biochim. Biophys. Acta 1582, 45–51 (2002).
  CAS PubMed Google Scholar
• Tanyi, J. L. et al. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res. 63, 1073–1082 (2003). Genetic validation of LPA production and action as a therapeutic target in ovarian cancer.
  CAS PubMed Google Scholar
• Xu, Y. et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280, 719–723 (1998). Provocative preliminary data indicating that measurement of lysophospholipids might allow for early diagnosis of cancer.
  CAS PubMed Google Scholar
• Baker, D. L. et al. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA 287, 3081–3082 (2002). Careful analysis of the levels of LPA in plasma in ovarian cancer. Failed to confirm that plasma LPA levels are significantly increased in ovarian cancer patients.
  PubMed Google Scholar
• Hama, K., Bandoh, K., Kakehi, Y., Aoki, J. & Arai, H. Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors. FEBS Lett. 523, 187–192 (2002).
  CAS PubMed Google Scholar
• Gerrard, J. M. & Robinson, P. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim. Biophys. Acta 1001, 282–285 (1989).
  CAS PubMed Google Scholar
• Ginestra, A., Miceli, D., Dolo, V., Romano, F. M. & Vittorelli, M. L. Membrane vesicles in ovarian cancer fluids: a new potential marker. Anticancer Res 19, 3439–3445 (1999).
  CAS PubMed Google Scholar
• Andre, F. et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360, 295–305 (2002).
  CAS PubMed Google Scholar
• Stracke, M. L. et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J. Biol. Chem. 267, 2524–2529 (1992). Identification of autotaxin as a motogen. Autotaxin would eventually be shown to be lysoPLD, the key enzyme regulating LPA production.
  CAS PubMed Google Scholar
• Murata, J. et al. cDNA cloning of the human tumour motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases. J. Biol. Chem. 269, 30479–30484 (1994).
  CAS PubMed Google Scholar
• Nam, S. W. et al. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res. 61, 6938–6944 (2001). Describes the role of autotaxin in neovascularization in vivo.
  CAS PubMed Google Scholar
• Koh, E. et al. Site-directed mutations in the tumor-associated cytokine, autotaxin, eliminate nucleotide phosphodiesterase, lysophospholipase D, and motogenic activities. Cancer Res. 63, 2042–2045 (2003).
  CAS PubMed Google Scholar
• Clair, T. et al. Autotaxin hydrolyzes phospholipids to produce a migration stimulator, lysophosphatidic acid, or a migration inhibitor, sphingosine-1-phosphate. Cancer Res. (in the press).
• Gijsbers, R., Aoki, J., Arai, H. & Bollen, M. The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site. FEBS Lett. 538, 60–64 (2003).
  CAS PubMed Google Scholar
• Bachner, D. et al. Bmp-2 downstream targets in mesenchymal development identified by subtractive cloning from recombinant mesenchymal progenitors (C3H10T1/2). Dev. Dyn. 213, 398–411 (1998).
  CAS PubMed Google Scholar
• Tice, D. A. et al. Synergistic induction of tumour antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling. J. Biol. Chem. 277, 14329–14335 (2002).
  CAS PubMed Google Scholar
• Croset, M., Brossard, N., Polette, A. & Lagarde, M. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem. J. 345, 61–67 (2000).
  CAS PubMed PubMed Central Google Scholar
• Nam, S. W. et al. Autotaxin (ATX), a potent tumour motogen, augments invasive and metastatic potential of ras-transformed cells. Oncogene 19, 241–247 (2000). Describes the role of autotaxin in the metastatic cascade in vivo.
  CAS PubMed Google Scholar
• Yang, S. Y. et al. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin. Exp. Metastasis 19, 603–608 (2002).
  CAS PubMed Google Scholar
• Tanyi, J. L. et al. 2003b Role of decreased levels of LPP-1 in accumulation of lysophosphatidic acid (LPA) in ovarian cancer. Clinical Cancer Res. (in the press).
• Xie, Y., Gibbs, T. C., Mukhin, Y. V. & Meier, K. E. Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells. J. Biol. Chem. 277, 32516–32526 (2002). Describes an autocrine LPA loop in the stimulation of prostate cancer cells.
  CAS PubMed Google Scholar
• Mills, G. B., May, C., McGill, M., Roifman, C. & Mellors, A. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization and mechanism of action. Cancer Res. 48, 1066–1071 (1988).
  CAS PubMed Google Scholar
• Mills, G. B. et al. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian cancer cells. J. Clin. Invest. 86, 851–855 (1990).
  CAS PubMed PubMed Central Google Scholar
• Xu, Y. et al. Characterization of an ovarian cancer activating factor (OCAF) in ascites from ovarian cancer patients. Clin. Cancer Res. 1, 1223–1232 (1995). Shows that ascites from ovarian cancer patients contain high levels of bioactive LPA, including unusual LPA isoforms.
  CAS PubMed Google Scholar
• Westermann, A. M. et al. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann. Oncol. 9, 437–442 (1998).
  CAS PubMed Google Scholar
• Xiao, Y. J. et al. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal. Biochem. 290, 302–313 (2001).
  CAS PubMed Google Scholar
• Shen, Z., Belinson, J., Morton, R. E., Xu, Y. & Xu, Y. Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol. Oncol. 71, 364–368 (1998).
  CAS PubMed Google Scholar
• Okita, M. Abnormal plasma lysophosphatidic acid level in ovarian cancer patients. Bulletin of Faculty of Health and Welfare Science, Okayama Prefectural University 1, 29–35 (1994).
  Google Scholar
• Sasagawa, T., Suzuki, K., Shiota, T., Kondo, T. & Okita, M. The significance of plasma lysophospholipids in patients with renal failure on hemodialysis. J. Nutr. Sci. Vitaminol. 44, 809–818 (1998).
  CAS PubMed Google Scholar
• Sasagawa, T., Okita, M., Murakami, J., Kato, T. & Watanabe, A. Abnormal serum lysophospholipids in multiple myeloma patients. Lipids 34, 17–21 (1999).
  CAS PubMed Google Scholar
• Okita, M., Gaudette, D. C., Mills, G. B. & Holub, B. J. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients. Int. J. Cancer 71, 31–34 (1997).
  CAS PubMed Google Scholar
• Yoon, H. R., Kim, H. & Cho, S. H. Quantitative analysis of acyl-lysophosphatidic acid in plasma using negative ionization tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 788, 85–92 (2003).
  CAS PubMed Google Scholar
• Shen, Z. et al. Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Gynecol. Oncol. 83, 25–30 (2001).
  CAS PubMed Google Scholar
• Tokumura, A. et al. Lack of significant differences in the corrected activity of lysophospholipase D, producer of phospholipid mediator lysophosphatidic acid, in incubated serum from women with and without ovarian tumors. Cancer 94, 141–151 (2002).
  CAS PubMed Google Scholar
• Deng, W. et al. Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis. Gastroenterology 123, 206–216 (2002). Indicates that compounds that mimic LPA could decrease toxicity associated with cancer therapy under appropriate conditions.
  CAS PubMed Google Scholar